Current Osteoporosis Reports ( IF 4.2 ) Pub Date : 2023-12-14 , DOI: 10.1007/s11914-023-00833-3 Tatiane Vilaca 1, 2 , Richard Eastell 1
|
Purpose of the Review
The purpose of the review is to summarise the current scientific evidence on the efficacy of osteoporosis medications in patients with type 2 diabetes.
Recent Findings
Type 2 diabetes (T2D) is a growing global epidemic. The highest prevalence is observed in the elderly, the same population affected by osteoporosis. Despite normal or even increased bone mineral density and low bone turnover, T2D is associated with an increased risk of fractures in most skeletal sites. These findings raised concerns over the efficacy of anti-osteoporosis drugs in this population. There is no randomised controlled trial designed specifically for people with T2D. However, observational studies and post-hoc analyses of randomised controlled trials have provided valuable insights into the effects of various anti-osteoporosis treatments in this population. Overall, most anti-osteoporosis drugs seem to have similar efficacy and safety profiles for people with and without type 2 diabetes. However, continued research and long-term safety data are needed to optimise treatment strategies and improve bone health outcomes in this population.
Summary
The current evidence suggests that most anti-osteoporosis drugs exhibit comparable efficacy in people with and without T2D.
中文翻译：
骨质疏松症药物对 2 型糖尿病患者的疗效
审查的目的
该综述的目的是总结当前关于骨质疏松症药物对 2 型糖尿病患者疗效的科学证据。
最近的发现
2 型糖尿病 (T2D) 是一种日益严重的全球流行病。在老年人中观察到患病率最高，这一人群同样受到骨质疏松症的影响。尽管骨矿物质密度正常甚至增加且骨转换率低，但 T2D 与大多数骨骼部位骨折的风险增加有关。这些发现引起了人们对该人群抗骨质疏松药物疗效的担忧。目前还没有专门针对 2 型糖尿病患者设计的随机对照试验。然而，观察性研究和随机对照试验的事后分析为了解各种抗骨质疏松治疗对该人群的效果提供了有价值的见解。总体而言，大多数抗骨质疏松药物对于 2 型糖尿病患者和非 2 型糖尿病患者似乎具有相似的疗效和安全性。然而，需要持续的研究和长期的安全数据来优化治疗策略并改善该人群的骨骼健康结果。
概括
目前的证据表明，大多数抗骨质疏松药物对患有和未患有 T2D 的人表现出相当的疗效。
京公网安备 11010802027423号